Target
Roche
2 abstracts
Abstract
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute (Netherlands), Hartwig Medical Foundation, Erasmus Medical Cancer Institute, Department of Biometrics,
Abstract
Two-year lung cancer survival between 2000 to 2020: Results from 3 French nationwide cohorts.Org: Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France, CHI De Creteil, Créteil, France, HIA SAINTE ANNE, Toulon, France, Hospital Center De La Cote Basque, Bayonne, France, Centre Hospitalier, Le Mans, France,